Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic DiseasesPHILADELPHIA and COPENHAGEN, Denmark, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced its launch with a $159.8 million Series A financing. Proceeds from the financing will support Phase 2 clinical development of ALV-100, the company’s lead program, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.
